Nurix Therapeutics, Inc. (NASDAQ:NRIX)
| Market Cap | 2.36B+131.2% |
| Revenue (ttm) | 36.77M-58.4% |
| Net Income | -341.35M-64.6% |
| EPS | -3.45-32.2% |
| Shares Out | 103.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,508,783 |
| Open | 22.43 |
| Previous Close | 22.60 |
| Day's Range | 22.18 - 23.10 |
| 52-Week Range | 8.20 - 28.23 |
| Beta | 1.82 |
| Analysts | Buy |
| Price Target | 34.67(+52.53%) |
| Earnings Date | Oct 8, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About NRIX
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$NRIX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in NRIX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NRIX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NRIX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
NRIX Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Bexobrutideg (NX-5948) | $28.19M | 90.66% |
| NX-1607 | $1.74M | 5.59% |
| Zelebrudomide (NX-2127) | $1.17M | 3.75% |
As of: Q2 2026 (May 31, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New NRIX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NRIX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NRIX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $84.66M |
| IWMiShares Russell 2000 ETF | $56.75M |
| XBIState Street SPDR S&P Biotech ETF | $51.90M |
| ARKGARK Genomic Revolution ETF | $40.43M |
| VXFVanguard Extended Market ETF | $29.15M |
| IBBiShares Biotechnology ETF | $16.90M |
Estimated from each fund’s disclosed top holdings × AUM
NRIX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from NRIX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score